Node Positive Renal Cell Cancer. Who Can Be Helped?

European Urology

Volumn 51, Issue 6, 2007, Pages 1477-1478

  Messing, Edward M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; EDITORIAL; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEPHRECTOMY; OUTCOME ASSESSMENT; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; NEPHRECTOMY; PATIENT SELECTION; PROGNOSIS; REFERRAL AND CONSULTATION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34247381697     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.034     Document Type: Editorial

References (3)

1. Karakiewicz P.I., Trinh Q.-D., Bhojani N., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol. 51 (2007) 1616-1624
2. Pizzicaro J., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a mulitcentric randomized study. J Clin Oncol 19 (2001) 425-431
3. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alpha-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2 (2003) 1214-1222